MedinCell (FR0004065605 – MEDCL), a clinical stage pharmaceutical company developing a portfolio of longacting injectable products in various therapeutic areas (the “Company”), announces today a capital increase of €c.30 million through an offering to qualified investors, both French and international, by way of an accelerated bookbuilding process (the “Offering”).
Bryan, Garnier & Co Limited1 and ODDO BHF SCA are acting as Joint Global Coordinators and Joint Bookrunners.
Contacts
MedinCell announces a capital increase of a c.€30 million
February 10, 2021